Drug intelligence / Profile preview

Praxid

Development stage: Unknown
Lead developer: Neoceuticals
Modality: Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Praxid is a multi-ingredient natural dietary supplement developed by Neoceuticals for the management of heartburn and the promotion of digestive wellness. It is formulated as an effervescent powder containing a blend of ten nutraceuticals, including antacids (calcium and magnesium carbonates, potassium bicarbonate), mucosal protectants (deglycyrrhizinated licorice, zinc/L-carnosine), and digestive aids (gingerol, L-glutamine, papain, probiotics, and d-Limonene). Praxid is designed to provide immediate relief from acid reflux symptoms while supporting the integrity of the gastrointestinal lining and balancing gut microbiota, serving as a non-pharmaceutical alternative to proton pump inhibitors (PPIs).

Brand names: Praxid

Beyond the preview

Go deeper on Praxid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Praxid.

Explore the full profile